What’s the current market cap for Ambu A/S stock?

Ambu A/S (AMBUB) has a market cap of €2.2bn as of June 19, 2026.

What is the P/E ratio for Ambu A/S stock?

The price to earnings (P/E) ratio for Ambu A/S (AMBUB) stock is 34.71 as of June 19, 2026.

Does Ambu A/S stock pay dividends?

Yes, the Ambu A/S (AMBUB) stock pays dividends to shareholders. As of June 19, 2026, the dividend rate is €0.05488 and the yield is 0.66%. Ambu A/S has a payout ratio of 23.06% on a trailing twelve-month basis.

When is the next Ambu A/S dividend payment date?

The next Ambu A/S (AMBUB) dividend payment date is unconfirmed.

What is the beta indicator for Ambu A/S?

Ambu A/S (AMBUB) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Ambu A/S stock | €AMBUB Share Price

05:30

09:10

12:45

16:25

20:00

About Ambu A/S

Ambu A/S is a Danish company operating in the medical device industry, primarily involved in the development, manufacturing, and marketing of innovative healthcare solutions. The company's key products include single-use endoscopes, anesthesia devices, and patient monitoring and diagnostic solutions. Ambu was founded in 1937 and is headquartered in Ballerup, Denmark. It is known for its focus on single-use devices, which help reduce the risk of cross-contamination and improve efficiency in hospitals and clinics worldwide. The company's strategic positioning emphasizes innovation in medical technology and a strong commitment to addressing healthcare challenges globally.

Ticker

€AMBUB

Sector

Health

Primary listing

XGAT

Employees

5,200

Headquarters

Ballerup, Denmark

Website

www.ambu.com

Ambu A/S Metrics

BasicAdvanced

€2.2bn

34.71

€0.24

1.26

€0.05

0.66%

Bulls say / Bears say

Ambu achieved 8.6% organic revenue growth in Q1 2025/26, proving steady demand for its single-use solutions even with strong FX headwinds.

Ambu's Q1 presentation spotlighted its #1 position in the single-use endoscopy market, with the most comprehensive portfolio and largest direct commercial presence, confirming its leadership in this fast-growing segment.

After Q4, Ambu reaffirmed its full-year organic revenue growth target of 10–13% for FY 2025/26, showing management's confidence in its strategy and market potential.

FX and tariff headwinds reduced reported Q1 revenue growth to just 3.2%, highlighting Ambu's exposure to currency fluctuations.

Ambu shares have fallen 46.56% over the last twelve months, showing investor skepticism despite operational progress.

In Q4 FY 2024/25, Ambu reported an adjusted EBIT margin of 10.0%, below the 12.6% consensus, pointing to continued margin pressures.

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Bulls say / Bears say

Ambu achieved 8.6% organic revenue growth in Q1 2025/26, proving steady demand for its single-use solutions even with strong FX headwinds.

After Q4, Ambu reaffirmed its full-year organic revenue growth target of 10–13% for FY 2025/26, showing management's confidence in its strategy and market potential.

FX and tariff headwinds reduced reported Q1 revenue growth to just 3.2%, highlighting Ambu's exposure to currency fluctuations.

Ambu shares have fallen 46.56% over the last twelve months, showing investor skepticism despite operational progress.

In Q4 FY 2024/25, Ambu reported an adjusted EBIT margin of 10.0%, below the 12.6% consensus, pointing to continued margin pressures.

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

About Ambu A/S

Ticker

Primary listing

Employees

Headquarters

Ambu A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy €AMBUB

Lightyear

Legal

Work with us

Bulls say / Bears say

Ambu A/S/€AMBUB

About Ambu A/S

Ticker

Primary listing

Employees

Headquarters

Ambu A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

What’s the current market cap for Ambu A/S stock?

What is the P/E ratio for Ambu A/S stock?

Does Ambu A/S stock pay dividends?

When is the next Ambu A/S dividend payment date?

What is the beta indicator for Ambu A/S?

Bulls say / Bears say